Keryx Biopharma - KERX

[magolibero]

quanta abbondanza!

a guardare adesso il book (..all'alba..)
c'é in buco in vendiita da 0,986 a 2000

..duemila ??

 

[doctor NO]

a guardare adesso il book (..all'alba..)
c'é in buco in vendiita da 0,986 a 2000

..duemila ??

Ciao mago se mi danno 2000 $ ad azione vado a nuoto a portargliele comunque 0,83 alle 14h45

 

[Netzach]

a guardare adesso il book (..all'alba..)
c'é in buco in vendiita da 0,986 a 2000

..duemila ??

A qualcuno piace giocare ...

 

[magolibero]

sono proprio curioso di sapere cosa comunicano ad Orlando...
per il momento i venti sono favorevoli

oggi la prima dell 4 presentazioni

http://pharmapipeline.blogspot.com/2009/05/keryx-biopharmaceuticals-announces.html


====================

Renal Cell Carcinoma (RCC)

Friday, May 29th, 2009:

#5034: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.

Lead Author: Nicholas Vogelzang, MD

Poster Discussion: 5:00pm-6:00pm (Level 2, West Hall F5)

====================

Renal Cell Carcinoma (RCC

Sunday, May 31st, 2009:

#5101: A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI).

Lead Author: Daniel Cho, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)

====================

Colorectal Cancer

Sunday, May 31st, 2009:

#4081: Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

Lead Author: Sasha Vukelja, MD

Poster Session: 8:00am - 12:00pm (Level 2, West Hall C)

====================

Gastrointestinal Stromal Tumor (GIST)

Sunday, May 31st, 2009:

#10563: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

Lead Author: Anthony Conley, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)

 

[acqua+]

Ho la vaga impressione ,,,,, che con questa e i prox 3 interventi all'ASCO ,,,

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

http://finance.yahoo.com/news/Keryx-Biopharmaceuticals-prnews-15387317.html?.v=1

lunedì apre > 1 $

 

[acqua+]

Ho la vaga impressione ,,,,, che con questa e i prox 3 interventi all'ASCO ,,,

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

http://finance.yahoo.com/news/Keryx-Biopharmaceuticals-prnews-15387317.html?.v=1

lunedì apre > 1 $

ci siamo già ,,,, quasi

After Hours: 0.96

0.26 (37.14%) 4:44PM ET

 

[acqua+]

ci siamo già ,,,, quasi

After Hours: 0.96

0.26 (37.14%) 4:44PM ET

mi ricorreggo

After Hours: 1.08

0.38 (54.29%)

 

[acqua+]

,,, e NON sono degli scambini

After Hours

Last:$ 1.01
After Hours High:$ 1.20
After Hours Volume:531,488
After Hours Low:$ .74After Hours



http://www.nasdaq.com/aspxcontent/E...ymbol=ADH&symbol=KEYW&symbol=PDGE&symbol=BSIC

 

[acqua+]

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor


http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-newsArticle&ID=1293929&highlight=

 

[acqua+]

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer


http://www.abstract.asco.org/AbstView_65_35108.html